Yahoo Finance CompuGroup Medical SE KGaA Full Year 2023 Earnings: EPS Misses Expectations
CompuGroup Medical SE KGaA (ETR:COP) Full Year 2023 Results
Key Financial Results
Revenue: €1.23b (up 4.5% from FY 2022).
Net income: €45.9m (down 38% from FY 2022).
Profit margin: 3.7% (down from 6.2% in FY 2022). The decrease in margin was driven by higher expenses.
EPS: €0.88 (down from €1.41 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CompuGroup Medical SE KGaA EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 48%.
The primary driver behind last 12 months revenue was the Ambulatory Information Systems (AIS) segment contributing a total revenue of €576.3m (47% of total revenue). Notably, cost of sales worth €813.2m amounted to 66% of total revenue thereby underscoring the impact on earnings.Explore how COP's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in Germany.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 4 warning signs for CompuGroup Medical SE KGaA that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
